Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

pfizer aps - docetaxel - koncentrat til infusionsvæske, opløsning - 10 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

ebewe pharma ges.m.b.h. nfg. kg - epirubicinhydrochlorid - injektions-/infusionsvæske, opløsning - 2 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

baxter a/s - cyclophosphamid, vandfrit - overtrukne tabletter - 50 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

baxter a/s - cyclophosphamid, vandfrit - pulver til injektionsvæske, opløsning - 200 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - cyclophosphamid, vandfrit - overtrukne tabletter - 50 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - cyclophosphamid, vandfrit - pulver til injektionsvæske, opløsning - 1 g

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - cyclophosphamid, vandfrit - pulver til injektionsvæske, opløsning - 200 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomide - multipel sclerose - selektive immunosuppressiva - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotiske midler - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

viatris limited - clopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotiske midler - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segment elevation akut myokardieinfarkt, i kombination med asa i medicinsk behandlede patienter, der er berettiget til trombolytisk terapi. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. for yderligere oplysninger henvises der til afsnit 5.